The efficacy and safety of the targeted drug Osimertinib (Tagrisso) in the treatment of non-small cell lung cancer

Osimertinib (Tagrisso) is a targeted therapy drug mainly used to treat EGFR (epidermal growth factor receptor) mutant non-small cell lung cancer (NSCLC). EGFRmutation is one of the common driver gene mutations in NSCLC, which leads to abnormal proliferation and growth of tumors in a certain number of patients. Osimertinib (Tagressa)'s unique design makes it highly selective and effective against EGFR mutant tumors while reducing damage to normal cells. The following will discuss the effectiveness and safety of Osimertinib (Tagrisso) in the treatment of NSCLC through clinical trial data.

Clinical trial data

1. FLAURATest

The FLAURA trial is a pivotal clinical trial of osimertinib (Tagrisso) for the treatment of EGFR mutant NSCLC. The trial compared the efficacy and safety of osimertinib (Tagressa) with standard first-line therapy (a first- or second-generation EGFR tyrosine kinase inhibitor) in patients with EGFR-mutated advanced NSCLC.

Effectiveness data: The FLAURA trial showed that the progression-free survival (PFS) of the Osimertinib (Tagrisso) treatment group was significantly prolonged, and the median progression-free survival was extended from 10.2 months with standard treatment to osimertinib (Tagrisso) treatment group18.9 months. In addition, overall survival (OS) was also improved in the osimertinib (Tagressa) group.

Security data: In terms of security,The main adverse events of Osimertinib (Tagrisso) include mild to moderate side effects such as rash, diarrhea and fatigue. Compared with the standard treatment group, the Osimertinib (Tagrisso) group had a lower incidence of serious adverse events. In addition, the risk of cardiovascular toxicity was lower in the osimertinib (Tagrisso) group.

2. AURA3Test

The AURA3 trial is an important clinical trial of osimertinib (Tagrisso) for the treatment of EGFR T790M-positive advanced NSCLC. T790Mmutation is one of the main reasons why NSCLC patients become resistant to other EGFR inhibitors.

Efficacy data: The AURA3 trial showed that the median progression-free survival in the osimertinib (Tagrisso) treatment group was significantly extended, from 4.4 months in the chemotherapy control group to osimertinib (Tagrisso) treatment group 10.1 months. In addition, overall survival also improved in the osimertinib (Tagressa) group.

Safety data: In terms of safety, the main adverse events of osimertinib (Tagressa) include mild to moderate side effects such as rash, diarrhea, fatigue and drowsiness. Compared with the chemotherapy control group, the osimertinib (Tagrisso) group had a lower incidence of serious adverse events and a lower risk of cardiovascular toxicity.

Osimertinib (Tagressa) is a targeted therapy for EGFR mutantNSCLC, which has shown significant efficacy and good safety in clinical trials. Data from clinical trials such as FLAURA and AURA3 show that osimertinib (Tagrisso) can significantly prolong the progression-free survival and overall survival of patients, and shows a lower risk of toxic side effects and cardiovascular toxicity in terms of safety. Therefore, osimertinib (Tagressa)is widely regarded as an effective and safe treatment option, providing an important treatment option for EGFRmutantNSCLC patients. However, patients still need to be closely monitored and managed for possible side effects during treatment with Osimertinib (Tagressa) to ensure the safety and effectiveness of the treatment.